Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom April 27, 2022August 16, 2022
Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson’s Disease and Movement Disorders August 22, 2023August 22, 2023